McClung Michael R
Institute of Health and Ageing, Australian Catholic University, Melbourne, Australia.
Oregon Osteoporosis Center, 2881 NW Cumberland Road, Portland, OR 97210, USA.
Osteoporos Sarcopenia. 2017 Mar;3(1):8-17. doi: 10.1016/j.afos.2017.01.002. Epub 2017 Feb 15.
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand patients being followed for up to 10 years. Combined with more than six years of postmarketing experience, these studies provide substantial confidence that denosumab is a convenient and appropriate treatment for patients, including Asians, at high risk for fracture. This review will summarize the clinical development of denosumab and lessons learned since its approval for clinical use in 2010.
地诺单抗是一种特异性RANK配体抑制剂，是治疗绝经后骨质疏松症及相关疾病的新型疗法。一项广泛的临床开发项目评估了地诺单抗的临床疗效和安全性，数千名患者接受了长达10年的随访。结合六年多的上市后经验，这些研究充分证明，地诺单抗对于包括亚洲人在内的骨折高危患者是一种方便且合适的治疗方法。本综述将总结地诺单抗的临床开发情况以及自2010年批准临床使用以来所获得的经验教训。
